Get the Stockscreener App
11.08
9.81%
0.99
After Hours:
11.10
0.02
+0.18%
Biodesix Inc stock is traded at $11.08, with a volume of 292.65K.
It is up +9.81% in the last 24 hours and up +62.46% over the past month.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.
See More
Previous Close:
$10.09
Open:
$10.41
24h Volume:
292.65K
Relative Volume:
0.21
Market Cap:
$88.15M
Revenue:
$49.09M
Net Income/Loss:
$-52.15M
P/E Ratio:
-17.05
EPS:
-0.65
Net Cash Flow:
$-45.93M
1W Performance:
+24.22%
1M Performance:
+62.46%
6M Performance:
+24.19%
1Y Performance:
-47.24%
1-Day Range:
$10.31
$11.39
1-Week Range:
$8.50
$12.70
52-Week Range:
$3.436
$21.60
Biodesix Inc Stock (BDSX) Company Profile
Name
Biodesix Inc
Sector
Industry
Phone
303-417-0500
Address
919 WEST DILLON ROAD, LOUISVILLE
Compare BDSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
11.08 | 80.27M | 49.09M | -52.15M | -45.93M | -0.65 |
|
TMO
Thermo Fisher Scientific Inc
|
623.91 | 235.43B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.75 | 167.20B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
694.75 | 55.72B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
241.04 | 40.77B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
135.95 | 38.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-26-24 | Initiated | Craig Hallum | Buy |
| May-13-24 | Initiated | TD Cowen | Buy |
| May-03-24 | Initiated | Lake Street | Buy |
| Nov-17-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-23-20 | Initiated | BTIG Research | Buy |
| Nov-23-20 | Initiated | Canaccord Genuity | Buy |
| Nov-23-20 | Initiated | Morgan Stanley | Overweight |
| Nov-23-20 | Initiated | William Blair | Outperform |
View All
Biodesix Inc Stock (BDSX) Latest News
Hedge Fund and Insider Trading News: Seth Klarman, Dan Loeb, Michael Burry, Michael Platt, Bridgewater Associates, Greenlight Capital, Biodesix Inc (BDSX), UWM Holdings Corp (UWMC), and More - Insider Monkey
Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 80,000 Shares - MarketBeat
Biodesix (NASDAQ:BDSX) Director Acquires $236,000.00 in Stock - MarketBeat
Biodesix director Schuler buys $1.1m+ in BDSX stock By Investing.com - Investing.com Nigeria
Biodesix director Schuler buys $1.1m+ in BDSX stock - Investing.com
Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 82,465 Shares - MarketBeat
Biodesix (BDSX) emeritus director Schuler buys $903k in stock By Investing.com - Investing.com Nigeria
Biodesix (BDSX) emeritus director Schuler buys $903k in stock - Investing.com
Perkins Capital Management Inc. Has $397,000 Position in Biodesix, Inc. $BDSX - MarketBeat
Big Money Moves: Can Biodesix Inc expand into new marketsTrade Risk Summary & Entry Point Confirmation Signals - baoquankhu1.vn
Reviewing Biodesix (NASDAQ:BDSX) and HealthEquity (NASDAQ:HQY) - Defense World
How geopolitical tensions affect Biodesix Inc. stockWeekly Trade Review & High Accuracy Investment Entry Signals - bollywoodhelpline.com
BDSX stock shot up 23% pre-market today — what’s fueling the surge? - MSN
Biodesix Inc. (BDSX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Investors Still Aren't Entirely Convinced By Biodesix, Inc.'s (NASDAQ:BDSX) Revenues Despite 26% Price Jump - Sahm
Biodesix stock soars as preliminary results exceed guidance, achieves EBITDA profitability - Investing.com Nigeria
Quarterly Trades: Will Biodesix Inc stock rally after Fed decisions2025 Market Overview & Growth Focused Entry Point Reports - Bộ Nội Vụ
Biodesix: Strengthening Fundamentals, Emerging Profitability, and Strategic Growth Support Buy Rating and $20 Price Target - TipRanks
Biodesix: Strong Operational Momentum but Ongoing Capital Concerns Justify Hold Rating - TipRanks
Biodesix reports 41% revenue growth in Q4, exceeds 2025 guidance By Investing.com - Investing.com Nigeria
Biodesix sees stock soar after surpassing sales guidance - BizWest
BDSX Faces Financial Hurdles as Stock Volatility Heightens - StocksToTrade
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability - FinancialContent
BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? - Asianet Newsable
Biodesix Stock Rebounds on Strategic Plans for Market Expansion - timothysykes.com
This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why - Stocktwits
Biodesix (BDSX) Surges 41% on Strong Preliminary Q4 and FY Resul - GuruFocus
Biodesix Surges On Strong Preliminary Q4 And FY2025 Revenue Results - Nasdaq
Biodesix skyrockets 43%, expects FY revenue to beat guidance - MSN
Biodesix (BDSX) Surpasses 2025 Revenue Expectations with Strong Q4 Performance - GuruFocus
Biodesix reports 41% revenue growth in Q4, exceeds 2025 guidance - Investing.com
Biodesix, Inc. Reports Estimated Q4 2025 Revenue of $28.8 Million, Achieving 41% Growth and Full-Year Revenue of $88.5 Million, Up 24% - Quiver Quantitative
Biodesix prelim Q4 revenue beats expectations, helped by growth in Lung Diagnostics - TradingView
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) - bdtonline.com
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 325.67%: Here's is How to Trade - MSN
Is Biodesix Inc. stock affected by interest rate hikesWeekly Investment Summary & Daily Chart Pattern Signals - Улправда
What dividend safety score for Biodesix Inc. stockDurability and Wear Notes & HOKA model picks for your routine - ulpravda.ru
Will Biodesix Inc. stock split again soonTreasury Yields & Capital Efficiency Focused Ideas - ulpravda.ru
Will Biodesix Inc. stock benefit from automationMarket Risk Report & Fast Exit/Entry Strategy Plans - Улправда
BDSX stock touches 52-week low at $1 amid market challenges - MSN
Fundamentals Check: Why analysts recommend Modine Manufacturing Company MMF stockJuly 2025 Market Mood & Free Real-Time Market Sentiment Alerts - moha.gov.vn
Biodesix Jumps 46% As Insider Buying, Retail Optimism Offset Scotiabank Target Cut - MSN
Biodesix CFO sells $22,794 in stock - MSN
Biodesix Inc Stock (BDSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):